A 群C 群脑膜炎球菌多糖结合疫苗和乙肝疫苗同时接种后疑似预防接种异常反应监测分析  

Surveillance analysis of adverse events following co-immunization ofgroup A and group C meningococcal polysaccharide conjugate vaccineand hepatitis B vaccine

作　　者：王斌冰[1] 薛文庆 孟凡亚[1] 唐继海[2] 罗献伟[1] 苏颖[1] 董燕 王军平 Wang Binbing;Xue Wenqing;Meng Fanya;Tang Jihai;Luo Xianwei;Su Ying;Dong Yan;Wang Junping(Department of Immunoprophylaxis,Anhui Provincial Center for Disease Control and Prevention;Center for Clinical Evaluation of Vaccines,Anhui Provincial Center for Disease Control and Prevention)

机构地区：[1]安徽省疾病预防控制中心免疫预防科,合肥230601 [2]安徽省疾病预防控制中心疫苗临床评价中心,合肥230601

出　　处：《重庆医科大学学报》2025年第1期88-93,共6页Journal of Chongqing Medical University

基　　金：中国肝炎防治基金会中国乙肝防控科研基金资助项目(编号:YGFK20230119)

摘　　要：目的:评价A群C群脑膜炎球菌多糖结合疫苗(group A and group C meningococcal polysaccharide conjugate vaccine,MPCV-AC)和乙型肝炎疫苗(hepatitis B vaccine,HepB)同时接种后的安全性。方法:通过国家免疫规划信息系统和安徽省免疫规划信息管理系统分别收集2020年至2022年安徽省适龄儿童MPCV-AC和HepB的疑似预防接种异常反应(adverse events following immunization,AEFI)数据和预防接种数据,比较2种疫苗同时接种和单独接种的AEFI的发生风险。结果:MPCV-AC第1剂次和HepB第3剂次同时接种、MPCV-AC第1剂次单独接种、HepB第3剂次单独接种的AEFI报告发生率分别为48.03/10万(280例)、56.37/10万(314例)、51.96/10万(283例);其中一般反应分别为43.91/10万(256例)、51.35/10万(286例)、48.65/10万(265例),异常反应分别为4.12/10万(24例)、4.85/10万(27例)、3.30/10万(18例)。同时接种组、单独接种组的AEFI发生风险、一般反应及异常反应的发生风险差异均无统计学意义。结论:MPCV-AC和HepB同时接种未增加AEFI的发生风险,可作为6月龄儿童同时接种MPCV-AC和HepB的科学依据。Objective:To assess the safety of co-immunization of group A and group C meningococcal polysaccharide conjugate vaccine(MPCV-AC)and hepatitis B vaccine(HepB).Methods:The data on adverse event following immunization(AEFI)and vaccination with MPCV-AC and HepB among age-eligible children in Anhui Province,China from 2020 to 2022 were obtained through the National Immunization Information System and Anhui Provincial Immunization Information System.The reported incidence rates of AEFI were compared among children who received the two vaccines simultaneously and separately.Results:The reported incidence rates of AEFI were 48.03/105(280 cases)following co-immunization of MPCV-AC(1st dose)and HepB(3rd dose),56.37/105(314 cases)following MPCV-AC(1st dose),and 51.96/105(283 cases)following HepB(3rd dose).The incidence rates of common reactions in the three groups were 43.91/105(256 cases),51.35/105(286 cases),and 48.65/105(265 cases),respectively;the incidence rates of adverse events in the three groups were 4.12/105(24 cases),4.85/105(27 cases),and 3.30/105(18 cases),respectively.There were no significant differences between the co-immunization group and the separate vaccination groups in the risk of AEFI,common reactions,and adverse events.Conclusion:Co-immunization of MPCV-AC and HepB does not increase the risk of AEFI,which can serve as a scientific basis for co-immunization of MPCV-AC and HepB in 6-month-old children.

关 键 词：AC结合疫苗 乙肝疫苗 同时接种 疑似预防接种异常反应 

分 类 号：R186[医药卫生—流行病学]